Assetmark Inc. Acquires 11,875 Shares of Johnson & Johnson $JNJ

Assetmark Inc. lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 10.9% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 121,277 shares of the company’s stock after purchasing an additional 11,875 shares during the period. Assetmark Inc.’s holdings in Johnson & Johnson were worth $22,487,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of JNJ. Brighton Jones LLC increased its position in Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after purchasing an additional 6,332 shares during the period. United Bank boosted its stake in shares of Johnson & Johnson by 110.7% in the 1st quarter. United Bank now owns 9,279 shares of the company’s stock valued at $1,539,000 after purchasing an additional 4,876 shares during the last quarter. Sivia Capital Partners LLC increased its position in shares of Johnson & Johnson by 13.4% during the second quarter. Sivia Capital Partners LLC now owns 5,863 shares of the company’s stock worth $896,000 after buying an additional 692 shares during the period. Wealth Group Ltd. raised its stake in Johnson & Johnson by 12.8% during the second quarter. Wealth Group Ltd. now owns 1,482 shares of the company’s stock worth $226,000 after buying an additional 168 shares during the last quarter. Finally, Sendero Wealth Management LLC lifted its holdings in Johnson & Johnson by 4.2% in the second quarter. Sendero Wealth Management LLC now owns 8,353 shares of the company’s stock valued at $1,276,000 after buying an additional 337 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: New clinical data — 12‑month pilot results for the OMNY‑AF/OMNYPULSE atrial‑fibrillation platform showed strong success, supporting J&J’s device pipeline and longer‑term growth prospects. Johnson & Johnson (JNJ) Reports 100% Success in OMNY-AF Study
• Positive Sentiment: High‑profile endorsement — Jim Cramer publicly praised J&J, which can lift retail sentiment and trading interest in the near term. Johnson & Johnson (JNJ) is amazing, says Jim Cramer
• Positive Sentiment: Investor interest — coverage noting hedge‑fund ownership and favorable research commentary highlights institutional demand for JNJ as a defensive, cash‑generative mega‑cap. Why is Johnson & Johnson (JNJ) One of the Best Medical Research Stocks to Buy According to Hedge Funds?
• Neutral Sentiment: Analyst/valuation discussion — commentary (Forbes) examines whether JNJ remains attractive after a large multi‑quarter rally, noting strong fundamentals but higher expectations. This may temper upside but doesn’t change fundamentals. After A 55% Surge, Is JNJ Stock Still A Buy?
• Neutral Sentiment: Minor analyst action — Wall Street Zen cut JNJ to Hold, a modest signal that could pressure sentiment but not a major catalyst by itself. Johnson & Johnson (NYSE:JNJ) Cut to Hold at Wall Street Zen
• Negative Sentiment: Legal headline risk — A Pennsylvania jury found J&J liable in a talc/ovarian‑cancer case and awarded $250,000 to the plaintiff’s family. While the award is modest, the ruling renews media focus on J&J’s long‑running talc litigation and could sustain volatility or incremental settlement exposure. Pennsylvania jury finds Johnson & Johnson liable for cancer in latest talc trial Philadelphia Jury Returns $250,000 Verdict Against J&J

Johnson & Johnson Trading Down 0.5%

Shares of JNJ stock opened at $243.37 on Friday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.80 and a current ratio of 1.03. The company has a market capitalization of $586.51 billion, a price-to-earnings ratio of 22.02, a PEG ratio of 2.36 and a beta of 0.35. Johnson & Johnson has a 52-week low of $141.50 and a 52-week high of $246.35. The company has a 50-day simple moving average of $217.25 and a two-hundred day simple moving average of $196.59.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Saturday, January 31st. The company reported $2.46 EPS for the quarter. The firm had revenue of $24.28 billion for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. Research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, February 24th. This represents a $5.20 annualized dividend and a dividend yield of 2.1%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 47.06%.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. Sanford C. Bernstein lifted their price objective on Johnson & Johnson from $208.00 to $225.00 and gave the stock a “market perform” rating in a research report on Friday, January 23rd. Guggenheim lifted their target price on Johnson & Johnson from $227.00 to $240.00 and gave the stock a “buy” rating in a report on Friday, January 23rd. Argus increased their price target on Johnson & Johnson from $210.00 to $240.00 in a report on Friday, January 23rd. UBS Group reiterated a “buy” rating on shares of Johnson & Johnson in a research note on Monday, January 5th. Finally, Leerink Partners increased their target price on shares of Johnson & Johnson from $201.00 to $232.00 and gave the stock a “market perform” rating in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $233.73.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.